Search Results - Holmes, F.

Free Holmes

Freeman Wright Holmes (6 June 1871–21 February 1967), better known as Free Holmes was an outstanding horse man who was involved with both thoroughbred and standardbred racing. He was born in Ashburton, South Canterbury, New Zealand.

He is notable for being both a champion driver and formerly a champion jockey. He won a unique double of the New Zealand Cup in 1888 for thoroughbreds, at Riccarton, riding Manton, and in 1919 driving Trix Pointer to win the NZ Trotting Cup at the Addington Raceway. As a jockey, he also won the 1894 Grand National Hurdles and 1895 Great Northern Hurdles and Great Northern Steeplechase with Liberator. He was also an expert in the management of thoroughbred horses. He successfully trained and owned horses both over the fences and on the flat.

He was known as "The Grand Old Man of Trotting". and "Old Free" in the trotting fraternity. He also rode and drove trotters. He won two Auckland Trotting Cups.

His son Maurice Holmes was also a driving legend. Provided by Wikipedia
  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 tria... by Chan, Arlene, Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S., Mansi, J., Barrios, C., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Zotano, A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M.

    Published 2016
    Get full text
  2. 2
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J., Barrios, C., Gnant, M., Tomaševic, Z., Denduluri, N., Šeparovic, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S., Jakobsen, E., Ciceniene, A., Inoue, K., Overkamp, F., Heijns, J., Armstrong, A., Link, J., Joy, A., Bryce, R., Wong, A., Moran, S., Yao, B., Xu, F., Auerbach, A., Buyse, M., Chan, Arlene, ExteNET Study Group

    Published 2017
    Get full text

Search Tools: